Insamo, Inc.

Pre-clinical drug development company designing membrane-permeable, cyclic-peptide molecules for inflammatory and other difficult to drug targets

Insamo was founded in 2022 by Tim Craven, Toby Passioura, and Glen McIntyre to revolutionize drug discovery by developing innovative “Intides” - membrane-permeable cyclic-peptide molecules. The founders are long-time colleagues and experts in their fields, with extensive experience in drug discovery, machine learning, and cyclic peptide technology. Current drug discovery approaches leave 55% of drug targets unreachable. Traditional small molecules and antibodies can only access 15% and 30% of targets, respectively. Insamo's proprietary platform combines machine learning, synthetic cyclic peptide molecular glue technology, and genetic code to design Intides with oral bioavailability and antibody-like binding capabilities. These Intides can target a wide range of therapeutic areas, including previously 'undruggable' targets. Their initial focus is on targeting inflammatory cytokines with orally available inhibitors.